Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | ||
Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete |